Catalog No.
Product Name
Application
Product Information
Citations
-
CYP51/HDAC Inhibitor
CYP51/HDAC-IN-1 is a potent dual inhibitor of CYP51 and HDAC, demonstrating significant biological activity in combating virulence factors as well as down-regulating resistance-associated genes. This compound shows promising therapeutic potential for treating tropical candidiasis and cryptococcal meningitis, making it a valuable tool for research in antifungal therapies. -
CYP3A4 Inhibitor
Escholtzine perchlorate is a potent CYP3A4 inhibitor derived from the alkaloid Eschscholzia californica. This compound demonstrates significant biological activity, with an IC50 value for CYP3A4 of 13.4 μM and an EC50 value for the 5-HT1A receptor of 11 μM. Escholtzine perchlorate is primarily utilized in research focused on anxiety and depression, offering valuable insights into pharmacological mechanisms related to these conditions. -
Fungal CYP51 Inhibitor
VT-1598 is an orally active and selective inhibitor of fungal cytochrome P450 51 (CYP51). It exhibits potent antifungal activity against Candida auris, making it a valuable tool for research into fungal infections. Additionally, VT-1598 contains an alkyne group, allowing it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) for click chemistry applications, facilitating the study of various biological interactions. -
CYP17A1/HDAC6 Inhibitor
CYP17A1/HDAC6-IN-1 is a dual inhibitor targeting both CYP17A1 and HDAC6, exhibiting IC50 values of 0.284 μM and 0.6015 μM, respectively. This compound demonstrates significant anti-tumor activity, making it a valuable tool for research in cancer biology. Its ability to simultaneously inhibit these targets suggests potential applications in therapeutic strategies against malignancies driven by steroidogenesis and histone deacetylation. -
CYP51 Inhibitor
CYP51-IN-30 is a potent inhibitor of CYP51, targeting sterol 14α-demethylase, an essential enzyme in sterol biosynthesis. This compound exhibits significant fungicidal activity, demonstrated by an EC50 value of 2.97 mg/L against Sclerotinia sclerotiorum. Its efficacy makes it a valuable tool for research in antifungal studies and applications in plant pathology. -
CYP51 Inhibitor
CYP51-IN-32 is a selective inhibitor of CYP51, demonstrating a potent antifungal activity with an IC50 of 0.331 μM against Candida albicans. This compound not only inhibits the growth of Candida albicans by disrupting hyphal formation and biofilm development, but it also releases hydrogen sulfide (H2S), contributing to its antifungal effects. CYP51-IN-32 is suitable for investigating Candida albicans infections and can be formulated into PEG-based nanovesicles for enhanced delivery in research applications. -
CYP51 Inhibitor
(Rac)-Ketoconazole is an imidazole antifungal agent that acts as a potent inhibitor of cytochrome P450-dependent 14α-sterol demethylase (CYP51). By disrupting ergosterol synthesis, it induces membrane dysfunction, thereby inhibiting the growth and reproduction of various fungi. This compound is primarily utilized in research relating to fungal infections and the mechanisms of antifungal resistance. -
Fungal CYP51A1 Inh
Becliconazole functions as an inhibitor of the fungal cytochrome P450 51A1 (CYP51A1) enzyme. This compound exhibits significant antifungal activity and is primarily utilized in research related to fungal infections, offering insights into the mechanisms of action and potential therapeutic interventions against fungal pathogens. -
CYP51 Inhibitor
Pipercroside A is a potent CYP51 inhibitor derived from Piper crocatum Ruiz & Pav. This compound exhibits significant antifungal activity, making it a valuable tool in studies of fungal infections and drug resistance mechanisms. Its role in inhibiting sterol biosynthesis positions Pipercroside A as a candidate for further investigation in antifungal therapeutic development. -
CYP51 Inhibitor
Pipercroside B is a potent inhibitor of CYP51, an essential enzyme in sterol biosynthesis. Isolated from Piper crocatum Ruiz & Pav, this compound exhibits significant antifungal activity, making it valuable for research into antifungal therapeutics. Its role in modulating CYP51 provides insights into fungal metabolism and potential treatment strategies against fungal infections. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-3 is a dual inhibitor targeting CYP51 and PD-L1, exhibiting potent antifungal activity with IC50 values of 0.205 μM and 0.039 μM, respectively. This compound induces early apoptosis in fungal cells by reducing levels of intracellular IL-2, NLRP3, and NF-κBp65 proteins. Additionally, CYP51/PD-L1-IN-3 causes mitochondrial damage and reactive oxygen species (ROS) accumulation, ultimately resulting in fungal lysis and cell death. This compound serves as a valuable tool for research in fungal infections and immune modulation. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-2 is a quinazoline compound that functions as a dual inhibitor of CYP51 and PD-L1, exhibiting IC50 values of 0.263 μM and 0.017 μM, respectively. It displays notable antifungal activity by triggering early apoptosis in fungal cells, leading to significant reductions in intracellular IL-2, NLRP3, and NF-κBp65 protein levels. Additionally, CYP51/PD-L1-IN-2 induces mitochondrial damage and reactive oxygen species (ROS) accumulation, culminating in fungal lysis and subsequent cell death. This compound is valuable for research exploring antifungal mechanisms and cancer immunotherapy. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-1 is a dual inhibitor targeting both CYP51 and PD-L1, exhibiting an IC50 of 0.884 μM for CYP51 and 0.083 μM for PD-L1. This quinazoline compound demonstrates notable antifungal activity by inducing early apoptosis in fungal cells while significantly reducing intracellular levels of IL-2, NLRP3, and NF-κBp65. Additionally, CYP51/PD-L1-IN-1 contributes to mitochondrial damage and reactive oxygen species (ROS) accumulation, ultimately leading to fungal lysis and cell death. This compound is valuable for research focused on antifungal therapies and immune modulation. -
CYP51 Inhibitor
CYP51-IN-19 is a potent inhibitor of cytochrome P450 51 (CYP51), a critical enzyme involved in sterol biosynthesis in fungi. This compound induces the generation of reactive oxygen species (ROS), leading to significant fungicidal activity. It is primarily utilized in antifungal research and the development of therapeutic agents targeting fungal infections. -
CYP1A2 Inhibitor
Frutinone A is a selective inhibitor of CYP1A2, featuring a chromonocoumarin structural scaffold. This compound exhibits notable antibacterial and antioxidant activities, making it a valuable tool for research in pharmacology and toxicology. Its ability to modulate the activity of CYP1A2 underscores its potential for studying drug metabolism and interactions. -
CYP2C19 Inhibitor
CYP2C19-IN-1 is a selective inhibitor of the cytochrome P450 enzyme CYP2C19, exhibiting a favorable safety profile with no hepatotoxicity or Ames test toxicity. It demonstrates potent inhibition of RNA-dependent RNA polymerase (RdRP) with a Ki value of 6.16 µM. This compound is primarily utilized in research focused on antiviral therapies against Zika virus (ZIKV). -
CYP3A Inhibitor
Troleandomycin, a macrolide antibiotic, functions as a selective inhibitor of the cytochrome P450 enzyme CYP3A. This compound is primarily used in research to investigate drug metabolism and interactions related to CYP3A. Additionally, it has applications in studies involving corticosteroids for conditions such as asthma, providing insights into therapeutic efficacy and safety profiles. -
CYP2D6 Substrate
3-Methoxyphenylethylamine is a substrate for cytochrome P450 2D6 (CYP2D6), playing a crucial role in drug metabolism. It is commonly used in research to investigate the metabolic pathways and enzyme interactions involving CYP2D6, making it valuable for studies on pharmacokinetics and drug-drug interactions. Additionally, this compound serves as an important intermediate in the synthesis of pharmaceuticals and other organic materials, furthering its applications in chemical research. -
JNK/CYP Inhibitor
JNK-IN-14 is a potent inhibitor of the c-Jun N-terminal kinase (JNK) family, demonstrating IC50 values of 1.81 nM for JNK1, 12.7 nM for JNK2, and 10.5 nM for JNK3. This compound effectively induces early apoptosis and causes cell cycle arrest in the G2/M phase. Additionally, JNK-IN-14 exhibits a modest inhibition of beclin-1 expression in K562 leukemia cells, indicating its potential application in cancer research and therapeutic strategies targeting JNK signaling pathways. -
CYP Isozymes Inhibitor
RPR203494 is a selective inhibitor of cytochrome P450 (CYP) isozymes, with significant activity against p38 mitogen-activated protein kinase, exhibiting an IC50 of 9 nM and an EC50 of 60 nM. This compound effectively inhibits hepatic CYP enzymes, making it a valuable tool in the study of drug metabolism and pharmacokinetics. RPR203494 holds potential for research applications related to rheumatoid arthritis and other inflammatory conditions, aiding in the exploration of therapeutic strategies targeting CYP-mediated pathways. -
CYP1B1
CYP1B1-IN-6 is a selective inhibitor of the cytochrome P450 enzyme CYP1B1. This compound demonstrates the ability to inhibit CYP1B1 activity, making it useful for tumor identification in fluorescence and photoacoustic imaging modalities. CYP1B1-IN-6 can assist in research applications focused on cancer diagnostics and the investigation of metabolic processes involving CYP1B1. -
GSK3β Inhibitor
GSK3β-IN-3 is an ATP-competitive inhibitor of glycogen synthase kinase 3 beta (GSK3β), exhibiting an IC50 of 0.90 μM. It effectively lowers the phosphorylation levels of tau protein in the BR5706 strain and reduces the accumulation of amyloid-beta (Aβ) aggregates in the CL2006 strain. This compound is essential for research applications focused on Alzheimer's disease (AD), aiding in the understanding of neurodegenerative mechanisms and potential therapeutic strategies. -
Cytochrome P450 Inhibitor
Kushenol K is a flavonoid antioxidant derived from the roots of Sophora flavescens, functioning as a selective inhibitor of cytochrome P450 3A4 (CYP3A4) with a Ki value of 1.35 μM. This compound exhibits weak antiviral activity against herpes simplex virus type 2 (HSV-2) with an EC50 of 147 μM. Additionally, Kushenol K inhibits sodium-glucose co-transporters SGLT1 and SGLT2, making it relevant for research in metabolic disorders and viral infections. -
CYP51 Inhibitor
Obtusifoliol is a selective inhibitor of cytochrome P450 51 (CYP51), demonstrating affinities with dissociation constants (Kd) of 1.2 μM for Trypanosoma brucei and 1.4 μM for human CYP51. This compound is significant in studies focused on trypanosomiasis, targeting the sterol biosynthesis pathway. Its inhibition of CYP51 may provide valuable insights into therapeutic strategies against related infections and contribute to the understanding of cholesterol metabolism in various biological systems. -
CYP3A4 Inhibitor
SR9186 is a selective inhibitor of CYP3A4, demonstrating potent inhibition with IC50 values of 9 nM for the metabolism of Midazolam, 4 nM for Testosterone, and 38 nM for Vincristine. This compound effectively impedes hepatic-stage P. falciparum development and obstructs the metabolism of ivermectin. Its utility extends to breast cancer research, making it a valuable tool for investigating drug metabolism and therapeutic applications. -
CypD Inhibitor
CypD-IN-5 is a selective inhibitor of cyclophilin D (CypD), a key regulator of mitochondrial permeability transition. This compound demonstrates significant potential in modulating mitochondrial function and may be particularly useful in studying neurodegenerative diseases such as Alzheimer's disease. Its application in research focuses on understanding the role of CypD in cellular stress responses and the underlying mechanisms of neurodegeneration. -
CYP3A Inhibitor
Cobicistat-d8 is a deuterated analog of Cobicistat, acting as a potent and selective inhibitor of cytochrome P450 3A (CYP3A) with IC50 values ranging from 30 to 285 nM. This reagent functions primarily as a pharmacokinetic enhancer, improving the absorption and bioavailability of anti-HIV agents. Its role in modulating drug metabolism makes it a valuable tool in pharmaceutical research and drug development. -
CYP3A Inhibitor
ALT-2074 is a CYP3A inhibitor with an IC50 value ranging from 2.0 to 2.6 μM, functioning as a catalytic analogue of glutathione peroxidase. Although it demonstrates a weak inhibitory effect on CYP3A in vivo, it serves as a valuable tool for studying the role of oxidative stress in inflammatory diseases, including acute coronary syndrome. This compound is particularly useful in research investigating the interplay between reactive oxygen species and metabolic pathways. -
CYP51 Inhibitor
VNI is a potent inhibitor of cytochrome P450 51 (CYP51), targeting sterol synthesis in the parasite Trypanosoma cruzi. Its mechanism of action disrupts the biosynthesis of essential sterols, leading to impaired growth and viability of the pathogen. VNI is primarily utilized in research focused on anti-parasitic strategies and the development of therapeutics for Chagas disease. -
CYP51 Inhibitor
CYP51-IN-15 is a selective inhibitor of CYP51, targeting the enzyme in Naegleria fowleri. With an EC50 value of 1.5 μM, it demonstrates potent biological activity against this pathogenic organism. This compound is valuable in research aimed at elucidating mechanisms of action and developing therapeutic strategies against Naegleria fowleri infections. -
CYP51 Inhibitor
LP8 is a pyridinyl-type inhibitor of cytochrome P450 51 (CYP51), specifically targeting the sterol biosynthesis pathway in various pathogens. This compound exhibits significant biological activity against Trypanosoma cruzi, the causative agent of Chagas disease and American trypanosomiasis. LP8 is valuable for research applications aimed at elucidating the mechanisms of these diseases and developing potential therapeutic strategies. -
CYP2C1/CYP2C19 Inhibitor
CYP2C1/CYP2C19-IN-2 is a potent inhibitor of the CYP2C1 and CYP2C19 enzymes. This compound exhibits minimal hepatotoxicity and lacks Ames toxicity, making it a safer choice for research applications. CYP2C1/CYP2C19-IN-2 is particularly useful in studies investigating antiviral mechanisms against Zika virus (ZIKV). -
CYP2C9/CYP2C19 Inhibitor
CYP2C9/CYP2C19-IN-1 is a potent inhibitor of the cytochrome P450 enzymes CYP2C9 and CYP2C19. This compound exhibits key biological activity by effectively modulating drug metabolism pathways without hepatotoxic effects or Ames toxicity. It serves as a valuable tool for research applications, including studies on anti-Zika virus (ZIKV) therapeutics. -
CYP1A1 Inhibitor
CYP1A1-IN-1 is a selective inhibitor of cytochrome P4501A1 (CYP1A1). This compound has demonstrated the ability to reduce bacterial loads of methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii through the enhancement of macrophage phagocytosis. CYP1A1-IN-1 holds potential for advancing research in sepsis associated with multidrug-resistant (MDR) bacterial infections. -
hCYP1B1 Inhibitor
hCYP1B1-IN-2 is a highly selective inhibitor of the human cytochrome P450 1B1 enzyme (hCYP1B1). It demonstrates remarkable potency in inhibiting hCYP1B1 activity, with an IC50 value of 0.040 nM, alongside a Ki value of 21.71 pM, indicating effective mixed inhibition. This compound also effectively disrupts aryl hydrocarbon receptor (AhR) transcription activities, making it a valuable tool for research applications focused on cancer and toxicology. -
hCYP1B1 Inhibitor
CYP1B1-IN-10 is a potent and selective inhibitor of human cytochrome P450 1B1 (hCYP1B1), exhibiting an IC50 value of 0.11 μM. This compound plays a significant role in the investigation of hormone-dependent tumors, including breast and ovarian cancers. Its specificity makes it a valuable tool for studying the therapeutic potential in oncology research. -
CYP1A1 Inducer
1,2,3,4,7,8,9-Heptachlorodibenzofuran is a potent inducer of CYP1A1 and CYP1B1 gene expression in human peripheral blood lymphocytes, promoting aryl hydrocarbon receptor repressor (AhRR) transcription. This compound enhances ethoxyresorufin-O-deethylase (EROD) activity, serving as a reliable biomarker for CYP1A1 activation. Additionally, it displays immunosuppressive properties by decreasing the number of splenic plaque-forming cells in mice while increasing aryl hydrocarbon hydroxylase (AHH) activity in liver microsomes. 1,2,3,4,7,8,9-Heptachlorodibenzofuran is valuable for research in immunology, metabolic disorders, and environmental toxicology. -
CYP1A1/1B1 Activator
1,2,3,4,7,8-Hexachlorodibenzofuran is a selective activator of the CYP1A1 and CYP1B1 enzymes. It induces the expression of these cytochrome P450 enzymes and aryl hydrocarbon receptor repressor (AhRR) in human peripheral blood lymphocytes. This compound also stimulates ethoxyresorufin-O-deethylase activity, achieving approximately 20% of the response observed with TCDD at a BMR20TCDD of 0.115-0.143 nM. Its ability to modulate these pathways makes it a valuable tool for studying biological responses to environmental pollutants and the mechanisms of xenobiotic metabolism. -
CYP2C9/CYP3A4 Inhibitor
AR-C141990 functions as a dual inhibitor of CYP2C9 and CYP3A4, exhibiting IC50 values of 16 μM for both enzymes. This compound is recognized for its significant bioactivity, particularly as it inhibits the monocarboxylate transporter MCT1 with a Ki value of 4.8 nM. AR-C141990 is employed in research applications focused on drug metabolism and pharmacokinetics, as well as studies investigating interactions between drugs and metabolic pathways. -
CYP1B1 Activator
17-HETE is a metabolite of arachidonic acid produced via cytochrome P-450 pathways, comprising the 17R-HETE and 17S-HETE enantiomers. It acts as an allosteric activator of cytochrome P450 1B1 and an ATPase inhibitor, thereby playing a significant role in the induction of cardiac hypertrophy. This compound is valuable for research in cardiovascular biology and cytochrome P450 enzyme activity. -
CYP1B1 Activator
17(S)-HETE is a metabolite of arachidonic acid produced via cytochrome P-450 pathways. This compound functions as an allosteric activator of cytochrome P450 1B1 and inhibits ATPase activity, which may contribute to the induction of cardiac hypertrophy. 17(S)-HETE is primarily utilized in research focusing on cardiovascular biology and cytochrome P450 enzyme functions. -
Stable Isotope
Verapamil-d3 hydrochloride is a deuterium-labeled derivative of the calcium channel blocker, verapamil hydrochloride. It serves as a potent inhibitor of P-glycoprotein (P-gp) and CYP3A4, facilitating detailed pharmacological studies. This stable isotope is primarily utilized in research related to hypertension, cardiac arrhythmias, and angina, providing insight into drug metabolism and transport mechanisms in various biological systems. -
CYP11A1 Inhibitor
Opevesostat is a selective inhibitor of CYP11A1, designed for oral administration. This compound demonstrates significant potential in the study of metastatic castration-resistant prostate cancer (mCRPC), supporting research into therapeutic approaches targeting steroidogenesis. Its specificity for CYP11A1 makes it a valuable tool in understanding the biochemical pathways involved in androgen synthesis and cancer progression. -
CYP3A4 Inhibtior
Curcumenol is a potent inhibitor of CYP3A4, exhibiting an IC50 value of 12.6 μM. This bioactive compound, derived from Curcuma zedoaria, demonstrates neuroprotective, anti-inflammatory, anti-tumor, and hepatoprotective activities. In studies, Curcumenol suppresses Akt-mediated NF-κB activation and inhibits the p38 MAPK signaling pathway in LPS-stimulated BV-2 microglial cells, making it a valuable tool for research in neuroinflammation and cancer therapy. -
CYP2C19 Inhibitor
(S)-(+)-N-3-Benzylnirvanol is a selective and competitive inhibitor of the cytochrome P450 isoform CYP2C19, exhibiting a Ki value of 250 nM. This compound displays low inhibition against other CYP isoforms, including CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, and CYP3A4. It is primarily utilized in pharmacological research to study drug metabolism and drug-drug interactions involving CYP2C19. -
CYP2J2 Inhibitor
LKY-047 is a selective reversible inhibitor of cytochrome P450 2J2 (CYP2J2), exhibiting an IC50 of 1.7 μM. This compound demonstrates high specificity, remaining inactive against other human cytochrome P450 isoforms, including CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A. LKY-047 is utilized in research applications focused on understanding the role of CYP2J2 in drug metabolism and cardiovascular diseases. -
CYP3A4 Inhibitor
6',7'-Dihydroxybergamottin (6′,7′-DHB) is a furanocoumarin that acts as a potent inhibitor of the cytochrome P450 enzyme CYP3A4. This compound is instrumental in studying drug metabolism and interactions, making it valuable for research in pharmacokinetics and toxicology. Its ability to modulate CYP3A4 activity has implications for understanding the effects of herbal supplements and dietary compounds on drug efficacy and safety. -
CYP Epoxygenase Inhibitor
MS-PPOH is a selective inhibitor of cytochrome P450 epoxygenases, primarily targeting CYP2C8 and CYP2C9 with IC50 values of 15 μM and 11 μM, respectively. This compound demonstrates key biological activity through the modulation of enzymatic metabolism pathways, making it valuable for research in pharmacology and toxicology. Additionally, MS-PPOH features an alkyne group, enabling its application in click chemistry via copper-catalyzed azide-alkyne cycloaddition (CuAAc) for tagging and labeling in various biochemical assays. -
CYP11B2 Inhibitor
Lorundrostat is a selective inhibitor of CYP11B2, targeting aldosterone synthase. This compound exhibits significant antihypertensive activity and is primarily utilized in research focused on the management of high blood pressure and related cardiovascular conditions. Its ability to modulate aldosterone levels makes it a valuable tool in studying endocrine and cardiovascular function. -
CYP3Aa Inhibitor
Azamulin is an irreversible, highly selective inhibitor of human CYP3A4, effectively targeting this crucial cytochrome P450 enzyme. With IC50 values ranging from 0.03 to 0.24 μM, Azamulin exhibits potent CYP3A inhibition, making it a valuable tool in the study of drug metabolism and pharmacokinetics. Additionally, it holds potential for research in anti-infection therapies, providing insights into therapeutic strategies against infectious agents.
